2 active not recruiting, 2 completed, 1 not yet recruiting, 1 recruiting. 8 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Active not recruiting 2, Completed 2, Not yet recruiting 1, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Unknown 1 |
Follow Plasmablastic Lymphoma: new trials by email Literature Review of Plasmablastic Lymphoma trials Research Report on Plasmablastic Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| QLS4131 Plus Isa-V-CHOP in Newly Diagnosed, HIV-Negative PBL: A Single-Center, Single-Arm, Phase II Study QLS4131 combined with Isa-V-CHOP - Plasmablastic Lymphoma | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2026-12-01 | 2026-11-06 |
| Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. Daratumumab, Bortezomib, Dexamethasone - Plasmablastic Lymphoma | Phase 2 | Recruiting | Fondazione Italiana Linfomi - ETS | 28 | 2022-07-11 | 2026-09-09 |
| Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma Belantamab Mafodotin - Relapsed Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma | Phase 2 | Terminated | Jacob Soumerai, MD | 10 | 2021-07-01 | 2026-03-13 |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Nivolumab, Varlilumab - ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2018-12-21 | 2026-11-13 |
| Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | AIDS Malignancy Consortium | 11 | 2016-06-23 | 2026-05-18 |
| Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride - Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma | Phase 1 / Phase 2 | Unknown | Northwestern University | 38 | 2015-10-28 | 2022-02-21 |
| Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide - AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 107 | 2010-10-06 | 2023-11-21 |
| Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma EPOCH-R, EPOCH-RR - Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive | Phase 2 | Completed | National Cancer Institute (NCI) | 194 | 2010-03-25 | 2023-04-27 |
Burkitt Lymphoma (4) · Lymphoma, Large B-Cell, Diffuse (4) · HIV Infections (3) · Lymphoma, B-Cell (2) · Lymphoma, Follicular (2) · Lymphoma, Primary Effusion (2) · HIV Seropositivity (1) · Hodgkin Disease (1) · Lymphoma (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Lymphomatoid Granulomatosis (1) · Recurrence (1)
Hemic and Lymphatic Diseases (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphatic Diseases (8) · Lymphoproliferative Disorders (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Lymphoma (7) · Lymphoma, Non-Hodgkin (7) · Lymphoma, B-Cell (6) · Infections (5) · Virus Diseases (5) · DNA Virus Infections (4) · Epstein-Barr Virus Infections (4) · Herpesviridae Infections (4)
Etoposide (4) · Cyclophosphamide (3) · Doxorubicin (3) · Prednisone (3) · Rituximab (3) · Vincristine (3) · Cytarabine (2) · deltacortene (2) · prednylidene (2) · Bortezomib (1) · CT-P10 (1) · Carmustine (1) · Dexamethasone (1) · Disulfides (1) · Hydrocortisone (1)
National Cancer Institute (NCI) (3) · AIDS Malignancy Consortium (1) · Fondazione Italiana Linfomi - ETS (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Jacob Soumerai, MD (1) · Northwestern University (1)
United States (6) · Italy (1)
Barbara Pro, MD (1) · Jacob Soumerai, MD (1) · Juan C Ramos (1) · Mark J Roschewski, M.D. (1) · Mehrdad Abedi (1) · Stephen M Ansell (1)
PMID 30501868, PMID 32430507, PMID 32453640, PMID 38237077
P30CA060553 (1), U01CA121947 (1), UM1CA121947 (1), UM1CA186686 (1), UM1CA186709 (1)